Detalhe da pesquisa
1.
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol
; 204(6): 2259-2263, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603594
2.
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724457
3.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
4.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
5.
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.
Blood
; 138(18): 1733-1739, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115096
6.
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Am J Hematol
; 98(4): 658-665, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683287
7.
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Am J Hematol
; 98(10): 1619-1626, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37485584
8.
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Am J Hematol
; 98(8): 1196-1203, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183966
9.
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
Am J Hematol
; 98(9): 1383-1393, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37334870
10.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
N Engl J Med
; 380(22): 2095-2103, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141631
11.
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Am J Hematol
; 97(3): 329-337, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981570
12.
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Am J Hematol
; 97(7): 856-864, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35357036
13.
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
Am J Hematol
; 97(7): 885-894, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35413152
14.
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Am J Hematol
; 97(11): 1413-1418, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054032
15.
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.
Am J Hematol
; 97(11): E408-E411, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054774
16.
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Am J Hematol
; 97(12): 1560-1567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087091
17.
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
Am J Hematol
; 97(12): 1599-1606, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117258
18.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Am J Hematol
; 97(8): 1035-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583199
19.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Am J Hematol
; 97(3): 322-328, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981560
20.
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Am J Hematol
; 97(11): 1443-1452, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054614